{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:00Z","timestamp":1747207320060,"version":"3.40.5"},"reference-count":36,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Atrial Fibrillation (AF) is common in the elderly. A key component of AF\nmanagement is Oral Anticoagulant Therapy (OAT), consisting of Vitamin K Antagonists (VKAs) or\nDirect Oral Anticoagulants (DOACs). The aim of the present study is to check, using STOPP (Screening\nTool of Older Persons\u2019 Prescriptions)\/START (Screening Tool to Alert to Right Treatment) Criteria,\nif such drugs are potentially inappropriately prescribed\/omitted in an elderly population with AF, and to\ndetermine their impact on mortality.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This study included patients (n = 427) with nonvalvular AF consecutively evaluated between\n2013 and 2019 at the Geriatric Outpatient Service, University Hospital of Monserrato, Cagliari, Italy,\nand followed up for 36 months. The OAT group included 330 patients; the other 97 patients constituted\nthe non-OAT group. The sample was assessed for STOPP\/START criteria.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>We found no difference (p &gt; 0.1) in comorbidity burden, frailty, and cardio-cerebro-vascular\ndisease prevalence in the two groups, which also did not present a difference in 36-month mortality (p =\n0.97). OAT was overall appropriately taken, and 62.4% of OAT-group presented the START criterion\nto take antiplatelets but also the STOPP criterion not to take them, because of the simultaneous anticoagulant\nintake. In the non-OAT group, 69.1% presented the START criterion to take anticoagulants, and\n21.6% the START criterion to take antiplatelets.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Patients with AF are often prone to under or over-prescription, particularly of antithrombotic\ndrugs. The STOPP\/START criteria are a valid tool to assess and correct wrong therapeutic choices.\nIn frail and comorbid subjects, survival is not correlated with the assumption of OAT.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161121666230418163016","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T05:25:18Z","timestamp":1684387518000},"page":"205-210","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["STOPP\/START Anti-aggregation and Anticoagulation Alerts in Atrial\nFibrillation"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4512-9161","authenticated-orcid":true,"given":"Francesco","family":"Salis","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, and Public Health, University of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Palimodde","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, and Public Health, University of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuele","family":"Rundeddu","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, and Public Health, University of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Mandas","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, and Public Health, University of Cagliari, Cagliari, Italy"},{"name":"University Hospital\n\u201cAzienda Ospedaliero-Universitaria\u201d of Cagliari, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-030-33330-0_3","volume":"1216","author":"Rohrmann S.","year":"2020","unstructured":"Rohrmann S.; Epidemiology of frailty in older people. Adv Exp Med Biol 2020,1216,21-27","journal-title":"Adv Exp Med Biol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"984046","DOI":"10.3389\/fmed.2022.984046","volume":"9","author":"Salis F.","year":"2022","unstructured":"Salis F.; Loddo S.; Zanda F.; Peralta M.M.; Serchisu L.; Mandas A.; Comprehensive geriatric assessment: Application and correlations in a real-life cross-sectional study. Front Med 2022,9,984046","journal-title":"Front Med"},{"key":"ref=3","first-page":"233","volume":"40","author":"Laksmi P.W.","year":"2008","unstructured":"Laksmi P.W.; Harimurti K.; Setiati S.; Soejono C.H.; Aries W.; Roosheroe A.G.; Management of immobilization and its complication for elderly. Acta Med Indones 2008,40(4),233-240","journal-title":"Acta Med Indones"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/geriatrics8010012","volume":"8","author":"Salis F.","year":"2023","unstructured":"Salis F.; Costaggiu D.; Mandas A.; Mini-mental state examination: Optimal cut-off levels for mild and severe cognitive impairment. Geriatrics 2023,8(1),12","journal-title":"Geriatrics"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2174\/1871525713666150310112350","volume":"12","author":"Robles N.","year":"2015","unstructured":"Robles N.; Macias J.; Hypertension in the elderly. Cardiovasc Hematol Agents Med Chem 2015,12(3),136-145","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/diagnostics13020191","volume":"13","author":"Salis F.","year":"2023","unstructured":"Salis F.; Locci G.; Mura B.; Mandas A.; Anemia in elderly patients\u2014the impact of hemoglobin cut-off levels on geriatric domains. Diagnostics 2023,13(2),191","journal-title":"Diagnostics"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/00132580-200203000-00006","volume":"4","author":"Aronow W.S.","year":"2002","unstructured":"Aronow W.S.; Atrial fibrillation. Heart Dis 2002,4(2),91-101","journal-title":"Heart Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1134453","DOI":"10.3389\/fpubh.2023.1134453","volume":"11","author":"Salis F.","year":"2023","unstructured":"Salis F.; Palimodde A.; Demelas G.; Scionis M.I.; Mandas A.; Frailty and comorbidity burden in Atrial Fibrillation. Front Public Health 2023,11,1134453","journal-title":"Front Public Health"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.arr.2018.10.006","volume":"49","author":"Kato E.T.","year":"2019","unstructured":"Kato E.T.; Goto S.; Giugliano R.P.; Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev 2019,49,115-124","journal-title":"Ageing Res Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccl.2007.12.010","volume":"26","author":"Jacobs L.G.","year":"2008","unstructured":"Jacobs L.G.; Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Cardiol Clin 2008,26(2),157-167, v","journal-title":"Cardiol Clin"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1160\/TH13-11-0918","volume":"111","author":"Paikin J.S.","year":"2014","unstructured":"Paikin J.S.; Hirsh J.; Lauw M.N.; Eikelboom J.W.; Ginsberg J.S.; Chan N.C.; New oral anticoagulants for stroke prevention in atrial fibrillation: Impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost 2014,111(5),798-807","journal-title":"Thromb Haemost"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","volume":"31","author":"Di Minno A.","year":"2017","unstructured":"Di Minno A.; Frigerio B.; Spadarella G.; Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev 2017,31(4),193-203","journal-title":"Blood Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"Pisters R.","year":"2010","unstructured":"Pisters R.; Lane D.A.; Nieuwlaat R.; de Vos C.B.; Crijns H.J.G.M.; Lip G.Y.H.; A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010,138(5),1093-1100","journal-title":"Chest"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/ehjqcco\/qcaa082","volume":"7","author":"Ogawa H.","year":"2021","unstructured":"Ogawa H.; An Y.; Ishigami K.; Long-term clinical outcomes after major bleeding in patients with atrial fibrillation: The Fushimi AF registry. Eur Heart J Qual Care Clin Outcomes 2021,7(2),163-171","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.33963\/KP.15205","volume":"78","author":"Undas A.","year":"2020","unstructured":"Undas A.; Drabik L.; Potpara T.; Bleeding in anticoagulated patients with atrial fibrillation: Practical considerations. Kardiol Pol 2020,78(2),105-116","journal-title":"Kardiol Pol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.arr.2020.101092","volume":"61","author":"Bencivenga L.","year":"2020","unstructured":"Bencivenga L.; Komici K.; Nocella P.; Atrial fibrillation in the elderly: A risk factor beyond stroke. Ageing Res Rev 2020,61,101092","journal-title":"Ageing Res Rev"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.31083\/j.rcm2203074","volume":"22","author":"Bocchino P.P.","year":"2021","unstructured":"Bocchino P.P.; Angelini F.; Toso E.; Atrial fibrillation and coronary artery disease: A review on the optimal use of oral anticoagulants. Rev Cardiovasc Med 2021,22(3),635-648","journal-title":"Rev Cardiovasc Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ageing\/afu145","volume":"44","author":"O\u2019Mahony D.","year":"2014","unstructured":"O\u2019Mahony D.; O\u2019Sullivan D.; Byrne S.; O\u2019Connor M.N.; Ryan C.; Gallagher P.; STOPP\/START criteria for potentially inappropriate prescribing in older people: Version 2. Age Ageing 2014,44(2),213-218","journal-title":"Age Ageing"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.3390\/jcm11123465","volume":"11","author":"Loddo S.","year":"2022","unstructured":"Loddo S.; Salis F.; Rundeddu S.; Serchisu L.; Peralta M.M.; Mandas A.; Nutritional status and potentially inappropriate medications in elderly. J Clin Med 2022,11(12),3465","journal-title":"J Clin Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.semerg.2018.06.004","volume":"45","author":"Rodr\u00edguez-Blanco R.","year":"2019","unstructured":"Rodr\u00edguez-Blanco R.; \u00c1lvarez-Garc\u00eda M.; Villalibre-Calder\u00f3n C.; Pi\u00f1a-Ferreras L.D.; Junquera-Alonso S.; Alonso-Lorenzo J.C.; Evaluation of the update of the STOPP-START criteria in primary care. Semergen 2019,45(3),180-186","journal-title":"Semergen"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"988799","DOI":"10.3389\/fcvm.2022.988799","volume":"9","author":"Guo X.","year":"2022","unstructured":"Guo X.; Li M.; Du X.; Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study. Front Cardiovasc Med 2022,9,988799","journal-title":"Front Cardiovasc Med"},{"key":"ref=22","first-page":"237","volume":"11","author":"Coupet M.","year":"2013","unstructured":"Coupet M.; Renvoize D.; Rousseau C.; Fresil M.; Lozachmeur P.; Somme D.; Adequacy of cardiovascular prescriptions to good practice\nguides in the elderly according to the \"STOPP and START\"\ntools \u00bb. G\u00e9riatr Psychol Neuropsychiatr Vieil [Validity of cardiovascular prescriptions to the guidelines in the elderly according to the STOPP and START method].2013,11(3),237-243","journal-title":"G\u00e9riatr Psychol Neuropsychiatr Vieil"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s41999-019-00176-2","volume":"10","author":"Dubois-Puechlong S.","year":"2019","unstructured":"Dubois-Puechlong S.; Mille F.; Hindlet P.; Potentially inappropriate prescriptions of antithrombotic therapies in older outpatients: A French multicenter cross-sectional study. Eur Geriatr Med 2019,10(3),473-481","journal-title":"Eur Geriatr Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.lpm.2014.05.027","volume":"44","author":"Gentes \u00c9.","year":"2015","unstructured":"Gentes \u00c9.; Hertzog M.; Vogel T.; Lang P.O.; High frequency of potentially inappropriate cardiovascular drug prescriptions in the elderly population. Presse Med 2015,44(2),e41-e50","journal-title":"Presse Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e27990","DOI":"10.2196\/27990","volume":"6","author":"Rom\u00e1n-Villar\u00e1n E.","year":"2022","unstructured":"Rom\u00e1n-Villar\u00e1n E.; Alvarez-Romero C.; Mart\u00ednez-Garc\u00eda A.; A personalized ontology-based decision support system for complex chronic patients: Retrospective observational study. JMIR Form Res 2022,6(8),e27990","journal-title":"JMIR Form Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"Charlson M.E.","year":"1987","unstructured":"Charlson M.E.; Pompei P.; Ales K.L.; MacKenzie C.R.; A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987,40(5),373-383","journal-title":"J Chronic Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"Charlson M.","year":"1994","unstructured":"Charlson M.; Szatrowski T.P.; Peterson J.; Gold J.; Validation of a combined comorbidity index. J Clin Epidemiol 1994,47(11),1245-1251","journal-title":"J Clin Epidemiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12603-012-0084-2","volume":"16","author":"Morley J.E.","year":"2012","unstructured":"Morley J.E.; Malmstrom T.K.; Miller D.K.; A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2012,16(7),601-608","journal-title":"J Nutr Health Aging"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/ageing\/afq059","volume":"39","author":"Pamukcu B.","year":"2010","unstructured":"Pamukcu B.; Lip G.Y.H.; Lane D.A.; Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. Age Ageing 2010,39(5),533-535","journal-title":"Age Ageing"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e0270823","DOI":"10.1371\/journal.pone.0270823","volume":"17","author":"Su C.H.","year":"2022","unstructured":"Su C.H.; Lo C.H.; Chen H.H.; CHA2DS2-VASc score as an independent outcome predictor in patients hospitalized with acute ischemic stroke. PLoS One 2022,17(7),e0270823","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00392-021-01816-z","volume":"111","author":"Chao T.F.","year":"2022","unstructured":"Chao T.F.; Chan Y.H.; Chiang C.E.; Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. Clin Res Cardiol 2022,111(1),23-33","journal-title":"Clin Res Cardiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamacardio.2021.0038","volume":"6","author":"Gladstone D.J.","year":"2021","unstructured":"Gladstone D.J.; Wachter R.; Schmalstieg-Bahr K.; Screening for atrial fibrillation in the older population. JAMA Cardiol 2021,6(5),558-567","journal-title":"JAMA Cardiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1177\/2047487317715769","volume":"24","author":"Ruddox V.","year":"2017","unstructured":"Ruddox V.; Sandven I.; Munkhaugen J.; Skattebu J.; Edvardsen T.; Otterstad J.E.; Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol 2017,24(14),1555-1566","journal-title":"Eur J Prev Cardiol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1747493021995592","volume":"17","author":"Goulart A.C.","year":"2022","unstructured":"Goulart A.C.; Olmos R.D.; Santos I.S.; The impact of atrial fibrillation and long-term oral anticoagulant use on all-cause and cardiovascular mortality: A 12-year evaluation of the prospective Brazilian Study of Stroke Mortality and Morbidity. Int J Stroke 2022,17(1),48-58","journal-title":"Int J Stroke"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"afac146","DOI":"10.1093\/ageing\/afac146","volume":"51","author":"Takahashi M.","year":"2022","unstructured":"Takahashi M.; Okawa K.; Morimoto T.; Impact of direct oral anticoagulant use on mortality in very old patients with non-valvular atrial fibrillation. Age Ageing 2022,51(7),afac146","journal-title":"Age Ageing"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000509896","volume":"36","author":"Hink U.","year":"2020","unstructured":"Hink U.; Voigtl\u00e4nder T.; Necessity of antiaggregation and anticoagulation and its prognostic impact: A cardiologist\u2019s view. Visc Med 2020,36(4),264-273","journal-title":"Visc Med"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570161121666230418163016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216011\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570161121666230418163016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:16:38Z","timestamp":1694603798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216011\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161121666230418163016","relation":{},"ISSN":["1570-1611"],"issn-type":[{"type":"print","value":"1570-1611"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}